Doses Of Nandrolone Decanoate Research Articles

Nandrolone decanoate causes uterine injury by changing hormone levels and sex steroid receptors in a dose- and time-dependent manner

Different doses of nandrolone decanoate (ND) were used to investigate the expression of uterine sex steroid receptors (AR, ER-α, and ER-β) and the levels of serum sex hormones after treatment and recovery periods in adult rats. ND doses of 1.87, 3.75, 7.5, or 15 mg/kg b.w. or mineral oil (control group) were injected subcutaneously for 15 days, and the experimental groups were divided into three periods of evaluation: (a) ND treatment for 15 days, (b) ND treatment followed by 30-day-recovery and (c) ND treatment followed by 60-day-recovery. Estrous cycle was monitored daily. At the end of each experimental period, rats were euthanized for the collection of serum samples and uterine tissues. All animals showed persistent diestrus and only the highest ND dose was capable of inducing persistent diestrus until 60-day-recovery. Immunoexpression of uterine sex steroid receptors varied in a time-dependent manner. While AR expression was increase after treatment period, ER-α and ER-β expressions decreased after 60- and 30-day-recovery, respectively. ND also increased the serum levels of testosterone, 17β-estradiol, and dihydrotestosterone, especially at the highest doses of 7.5 and 15 mg ND/kg until 30 days of recovery. The levels of progesterone were significantly reduced in all ND-treated animals. No significant difference was observed in the levels of follicle-stimulating hormone, whereas the levels of luteinizing hormone varied according to specific dose and period. We conclude that uterine sex steroid receptors and sex hormones are affected by ND administration and these alterations can be only restored following lower doses and long recovery periods.

Lipid peroxidation and apoptotic response in rat brain areas induced by long-term administration of nandrolone: the mutual crosstalk between ROS and NF-kB.

The aim of this study was to evaluate the played by oxidative stress in the apoptotic response in different brain areas of rats chronically treated with supra‐physiological doses of nandrolone decanoate (ND). Immunohistochemical study and Western blot analysis were performed to evaluate cells' apoptosis and to measure the effects of expression of specific mediators, such as NF‐κB (nuclear factor kappa‐light‐chain‐enhancer of activated B cells), Bcl‐2 (B‐cell lymphoma 2), SMAC/DIABLO (second mitochondria‐derived activator of caspases/direct IAP‐binding protein with low PI) and VMAT2 (vesicular monoamine transporter 2) on apoptosis. The results of the present study indicate that a long‐term administration of ND promotes oxidative injury in rat brain specific areas. A link between oxidative stress and NF‐κB signalling pathways is supported by our results. In addition to high levels of oxidative stress, we consistently observed a strong immunopositivity to NF‐κB. It has been argued that one of the pathways leading to the activation of NF‐κB could be under reactive oxygen species (ROS)‐mediated control. In fact, growing evidence suggests that although in limited doses, endogenous ROS may play an activating role in NF‐κB signalling, while above a certain threshold, they may negatively impact upon this signalling. However, a mutual crosstalk between ROS and NF‐κB exists and recent studies have shown that ROS activity is subject to negative feedback regulation by NF‐κB, and that this negative regulation of ROS is the means through which NF‐κB counters programmed cells.

Effects of different doses of nandrolone decanoate on estrous cycle and ovarian tissue of rats after treatment and recovery periods.

This study tested the hypothesis that different doses of nandrolone decanoate (ND) will cause changes in the estrous cycle and ovarian tissue of adult rats; and investigated the duration of the recovery period that is sufficient to restore the damage in the animals treated with different doses. Wistar rats were treated with ND at doses of 1.87, 3.75, 7.5 and 15 mg/kg body weight, or received mineral oil (control group) for 15 days, subcutaneously. All animals were divided into three groups according to the treatment periods: (i) ND treatment for 15 days; (ii) ND treatment followed by a 30-day recovery; and (iii) ND treatment followed by a 60-day recovery. Estrous cycle was monitored daily, and at the end of each period, the animals were euthanized for histopathological analysis. During ND treatment and after 30-day recovery, all animals exhibited persistent diestrus. After a 60-day recovery, persistent diestrus was only maintained in the group that had received the highest dose. Ovarian weight was decreased significantly after the 30-day recovery, regardless of ND doses, compared with the control group. There was a reduction (P < 0.05) in the number of corpora lutea and antral and growing follicles, in contrast to an increase (P < 0.05) in atretic follicles in a dose- and time-dependent manner. Remarkable histopathological changes occurred in the ovaries of all ND-treated groups. In conclusion, the different doses of ND caused changes in the estrous cycle and ovarian tissue of rats, and recovery periods (30 and 60 days) were insufficient to completely restore the damage in the animals treated with the highest dose.

Dose-dependent effects and reversibility of the injuries caused by nandrolone decanoate in uterine tissue and fertility of rats.

This study is the first to investigate the effects of different doses of nandrolone decanoate (ND) upon uterine tissue and fertility, and if the reproductive alterations can be restored after cessation of the treatment. Wistar female rats were treated with ND at doses of 1.87, 3.75, 7.5, and 15 mg/kg body weight, diluted in vehicle (n = 30/group), or received only mineral oil (control group, n = 45). The animals were divided into three periods of study: ND-treated receiving a daily subcutaneous injection for 15 consecutive days (1), and treatment with ND followed by 30-day recovery (2), and 60-day recovery (3). At the end of each period, five females per group were induced to death to histopathological analysis and the others were allowed to fertility evaluation (at 19th gestational day). Animals that received ND followed by 30-day recovery exhibited persistent diestrous and marked suppression of reproductive capacity. Conversely, after 60-day recovery, only lowest doses females (1.87 and 3.75 mg/kg) exhibited restoration of normal estrous cyclicity. Uterine weights were increased after ND treatment similarly to that of the controls after 60-day recovery. The ND-treated groups showed histopathological changes in the endometrium, myometrium, and perimetrium, and an increase in the thickness of both muscular and serous layers. Notably, the recovery of uterine tissue after ND treatment was dose- and period-dependent. We reported that administration of ND promoted damage in uterine tissue and fertility of rats, and the recovery periods were insufficient to restore all of the side effects caused by ND under a dose-dependent response.

Chronic, supra‐physiological doses of nandrolone decanoate and exercise induced cardio‐toxicity in an animal‐model study

Chronic, supra‐physiological doses of nandrolone decanoate and exercise induced cardio‐toxicity in an animal‐model study

Efeito de diferentes doses de nandrolona associado ao treinamento de força sobre o perfil fenotípico e área de secção transversa do músculo de ratos

O presente estudo avaliou a influência de diferentes doses de decanoato de nandrolona (DN) associado ao Treinamento de Força (TF) sobre o fenótipo de fibras e área de secção transversa (AST) do músculo extensor longo dos dedos (EDL) em ratos "Wistar". Os animais foram divididos em sete grupos: controle (GC) e grupos de acordo com a concentração de DN (0,1, 1, 2, 5, 10 e 20 mg/kg) administrada intramuscular 3 vezes/semana. O TF consistiu de saltos em meio líquido (carga 50-70% do peso corporal) 3x/semana, durante cinco semanas. A associação do TF e DN promoveu ação modulatória sobre os tipos de fibras. Houve hipertrofia das fibras de contração rápida (tipo II) em comparação com as fibras de contração lenta (tipo I). Em conclusão, apesar da associação do TF com DN aumentar a AST muscular e alterar o fenótipo das fibras, não houve efeito gradual das doses mais altas.

Cholinergic system of rats treated with vincristine sulphate and nandrolone decanoate

This study aimed to detect brain and red blood cell acetylcholinesterase activity (AChE and RBC-AChE, respectively) of rats treated with vincristine sulphate and different doses of nandrolone decanoate. Thirty rats were divided into six groups (n = 5). The treatments were applied once a week for 2 weeks. Sample collection was performed in the third week. The groups were divided in: G1, physiologic solution (PS) (first and second week); G2, vincristine sulphate (4 mg/m2) in the first week and PS in the second week; G3, PS in the first week and nandrolone decanoate (1.8 mg/kg−1) in the second week; G4, PS in the first week and nandrolone decanoate (10 mg/kg−1) in the second week; G5, vincristine sulphate (4 mg/m2) in the first week and nandrolone decanoate (1.8 mg/kg−1) in the second week; and G6, vincristine sulphate (4 mg/m2) in the first week and nandrolone decanoate (10 mg/kg−1) in the second week. The isolated use of nandrolone decanoate and its use in association with vincristine sulphate altered brain AChE and RBC-AChE activity. These results suggest that there is interference in cholinergic neurotransmission, which could cause an alteration of its neurotransmitter, as well as a low or high stimulation of post-synaptic receptors. The serum RBC-AChE activity results presented in this study are similar to those exhibited by brain tissue.

Influence of anabolic steroid on anxiety levels in sedentary male rats

The aim of this study was to evaluate the influence of nandrolone decanoate on anxiety levels in rats. Male Wistar rats were treated with nandrolone decanoate (5mg/kg, two times per week, i.m.) or vehicle (propylene glycol—0.2 ml/kg, two times per week, IM) for 6 weeks. Control rats were subject only to procedures related to their routine husbandry. By the end of 6 weeks, all groups (24–29 rats/group) were submitted to the elevated plus maze test in order to evaluate their anxiety level. Some of these animals (12– 14/group) were treated with diazepam (1 mg/kg i.p.) 30 min before the elevated plus maze test. Nandrolone decanoate significantly decreased the percentage of time spent in the open arms (1.46 ± 0.49%) compared with control (3.80 ± 0.97%) and vehicle (3.96 ± 0.85%) groups, with no difference between control and vehicle treatments. The percentage of open arm entries was also reduced in the group treated with nandrolone decanoate in comparison with the vehicle and control. No changes in the number of closed arm entries were detected. Diazepam abolished the effects of nandrolone decanoate on the percentage of time in, and entries into the open arms. The present study showed that chronic treatment with a high dose of nandrolone decanoate increased the anxiety level in male rats.

Experience with refractory vitamin D-resistant rickets and non-17α alkyl testosterone derivative anabolic agent

Background: Renal tubular disorders may be associated vitamin D-resistant rickets, dwarfism and deformities. Treatment is nonspecific and directed towards correcting acidosis, hypokalemia, hypophosphatemia and vitamin D resistance. The response to therapy depends on the severity of the disorder, and sometimes bone changes persist with the development of skeletal deformities. Patients & methods: From June 2000 to 2001, four patients with renal tubular disorder associated with vitamin D-resistant rickets and deformities despite previous therapies, were observed. Of these patients, three have hereditary (autosomal recessive) proximal renal tubular acidosis affecting siblings with perfectly normal parents and grandparents, including two sisters, and one patient has X-linked dominant hypophosphatemic rickets. All have at least one sibling who died affected by the same disorder. Two boys, each with proximal renal tubular acidosis and X-linked dominant hypophosphatemic rickets were enrolled in a clinical study investigating the possibility of adding nandrolone to their conventional therapies to promote healing of rickets, provided both were males and having markedly delayed bone age together with close monitoring of bone age and careful observation for any sign of virilization. The boy with X-linked dominant hypophosphatemic rickets aged 18 months at enrollment, continued to have severe active rickets with the development of kyphosis despite 5 months of combined therapy with 1-alfacalcidol and phosphate supplementation. He received seven doses of nandrolone decanoate (12.5 mg) every 4 to 5 weeks. The boy with proximal renal tubular acidosis was aged 7 years at the time of addition of nandrolone to the conventional therapies of alfacalcidol, alkali and potassium supplementation. He also demonstrated severe active rickets and worsening of his bowing deformities. He received ten injections of nandrolone (25 mg) every 2 weeks. Nutritional support was provided for both and their skeletal age was monitored biweekly. Results: The novel addition of nandrolone resulted in a perfect radiological healing of rickets and growth acceleration without the occurrence of unwanted effects or advancement of bone age. The two sisters did not show any clinical or radiological improvement in their rickets and one of them died within 6 months of referral. Conclusion: The judicious use of nandrolone in carefully selected patients with refractory vitamin D-resistant rickets and significant delay of bone age was associated with a beneficial effect on healing of rickets and growth without any obvious adverse effect. This beneficial effect has to be confirmed by additional trials in the future.

Effects of Pharmacological Doses of Nandrolone Decanoate and Progressive Resistance Training in Immunodeficient Patients Infected with Human Immunodeficiency Virus

Effects of Pharmacological Doses of Nandrolone Decanoate and Progressive Resistance Training in Immunodeficient Patients Infected with Human Immunodeficiency Virus

Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study.

A prospective study of the evolution of serum erythropoietin level after androgen therapy was carried out in a group of 25 male patients on chronic hemodialysis treatment with nonferropenic anemia (serum ferritin > 50 ng/ml). The androgen used was nandrolone decanoate (200 mg/week intramuscularly, for 6 months). There was an increase of serum erythropoietin, that reached statistical significance in the 2nd week of treatment (8.6 +/- 6.4 vs. 14.2 +/- 9.8 mIU/ml, p < 0.05), and a stabilization after 1 month (1 month: 17.8 +/- 11.2 mIU/ml, 6 months: 19.6 +/- 14.9 mIU/ml). The hemoglobin also experienced a parallel increase to that observed in serum erythropoietin (basal value: 8 +/- 0.9 g/dl; at 1 month postandrogen: 9.2 +/- 1.3 g/dl, p < 0.001; at 6 months: 10.7 +/- 1.8 g/dl, p < 0.001). According to their response of serum erythropoietin the patients were divided into responders (15 patients) and nonresponders (10 patients). There were no differences between them concerning age, basal levels of serum erythropoietin and hemoglobin, and dose of nandrolone decanoate in relation to body weight. The evolution of hemoglobin was similar in both groups, and a correlation between serum erythropoietin and hemoglobin was not observed in the responder group. Fourteen patients were studied after androgen was discontinued. The serum erythropoietin returned to basal levels 6 weeks after the last dose of nandrolone decanoate (7.7 +/- 5.4 mIU/ml). However, hemoglobin was above the basal levels 16 weeks after discontinuing androgen (9.5 +/- 1.1 g/dl, p < 0.05), with no differences between the responder and nonresponder group.(ABSTRACT TRUNCATED AT 250 WORDS)